



## **Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019**

April 30, 2019

### **Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET**

SOUTH SAN FRANCISCO, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 5:30 AM Pacific Time/8:30 AM Eastern Time.

#### **Audio Webcast**

The webcast will be made available on the Company's website at [www.allogene.com](http://www.allogene.com) under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

#### **Dial-In Information**

Live (U.S./Canada): 1 (866) 940-5062

Live (International): 1 (409) 216-0618

Confirmation number: 6179933

#### **About Allogene Therapeutics**

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of "off-the-shelf" CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit [www.allogene.com](http://www.allogene.com), and follow @AllogeneTx on Twitter and LinkedIn.

#### **Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer, and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-K for the year ended December 31, 2018. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

#### **Allogene Media/Investor Contact:**

Christine Cassiano

Chief Communications Officer

(714) 552-0326

[Christine.Cassiano@allogene.com](mailto:Christine.Cassiano@allogene.com)



Source: Allogene Therapeutics, Inc.